The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche exercises option for Dyno's AAV vector in neurological gene therapy
Dyno Therapeutics has announced that Roche has exercised its option to license a novel AAV capsid for a gene therapy program targeting an undisclosed neurological disease, concluding their initial collaboration. This move triggers a $7 million payment to Dyno, with potential earnings exceeding $220 million in milestone payments and royalties. The partnership highlights Dyno's AI-driven gene delivery platform, which aims to enhance the effectiveness of gene therapies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.